- Based on the combined results of INTERACT-2 and ATACH-2, for spontaneous ICH patients presenting with an SBP of 150-220 mmHg, a target systolic blood pressure of 140 mm Hg is safe and can be effective for improving functional outcome.
- Based on the PATCH trial, platelet transfusion is not recommended in patients taking antiplatelet therapy prior to onset of spontaneous ICH.
- In patients with VKA (Vitamin K Antagonist) associated spontaneous ICH, BP reduction and INR reversal therapy should be initiated promptly and before transfer to tertiary care centers.
- In patients with VKA associated spontaneous ICH, the findings of the INCH trial suggest that PCC is better than FFP in normalizing the INR within 3 hours and reducing hematoma expansion at 3 and 24 hours, although those effects on overall clinical outcomes remain unclear.